Core Viewpoint - The company Saito Bio (300583.SZ) announced that its subsidiary Shandong Sry Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the marketing application of Methylprednisolone [1] Group 1: Company Developments - The approval pertains to Methylprednisolone, a medium-acting corticosteroid that is used in emergency treatment for critical illnesses [1] - Methylprednisolone is indicated for various conditions including endocrine disorders, rheumatic diseases, collagen diseases, skin diseases, allergic reactions, ophthalmic diseases, gastrointestinal diseases, blood diseases, leukemia, shock, cerebral edema, multiple neuritis, myelitis, and to prevent vomiting caused by cancer chemotherapy [1]

Core Viewpoint - The company, Tonghua Pharmaceutical (300636.SZ), has successfully passed the cGMP inspection conducted by the U.S. FDA, confirming compliance with U.S. drug production quality management standards [1] Group 1: Inspection Details - The cGMP inspection took place from August 4 to August 7, 2025, covering six major systems: quality system, materials, production, packaging and labeling, equipment facilities, and laboratory controls [1] - The company received confirmation from the U.S. FDA's official website that it has met the cGMP management standards [1]

Summary of Key Points Core Viewpoint - Haizheng Pharmaceutical announced on November 3 that as of the end of October 2025, the company has repurchased approximately 6.12 million shares, accounting for 0.51% of the total share capital, with a total expenditure of about 56.99 million yuan [1] Company Actions - The maximum purchase price for the repurchased shares was 10.55 yuan per share, while the minimum purchase price was 8.92 yuan per share [1]

Core Viewpoint - The announcement indicates that the company's subsidiary, Shandong Sry Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of Methylprednisolone, a corticosteroid used in various critical medical conditions [1] Group 1: Product Approval - Shandong Sry Pharmaceutical has been granted a marketing approval notice for Methylprednisolone [1] - Methylprednisolone is classified as a medium-acting, non-halogenated corticosteroid [1] Group 2: Medical Applications - The drug is utilized for emergency treatment in critical illnesses [1] - It is also indicated for endocrine disorders, rheumatic diseases, collagen diseases, skin diseases, allergic reactions, ophthalmic diseases, gastrointestinal diseases, hematological diseases, leukemia, shock, cerebral edema, multiple neuritis, myelitis, and to prevent vomiting caused by cancer chemotherapy [1]

Group 1 - The chemical pharmaceutical sector increased by 0.25% on November 3, with Asia-Pacific Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] - Asia-Pacific Pharmaceutical's stock price rose by 9.96% to 8.72, with a trading volume of 1.6689 million shares and a transaction value of 1.442 billion [1] Group 2 - The top gainers in the chemical pharmaceutical sector included HaiXiang Pharmaceutical, which rose by 9.93% to 6.31, and Tonghua Golden Horse, which increased by 8.37% to 28.10 [1] - The sector experienced a net outflow of 114 million from institutional investors, while retail investors saw a net outflow of 186 million, and speculative funds had a net inflow of 301 million [2][3] - The stock of YiPinHong decreased by 5.15% to 53.06, with a trading volume of 134,400 shares and a transaction value of 713 million [2]

Core Viewpoint - The company, Tonghe Pharmaceutical, has successfully passed the cGMP inspection by the FDA, indicating compliance with U.S. drug production quality standards [1] Group 1: FDA Inspection - The company underwent an FDA cGMP inspection from August 4 to August 7, 2025, covering six major systems: quality system, materials, production, packaging and labeling, equipment facilities, and laboratory controls [1] - The company has received confirmation from the FDA's official website that it has passed the inspection [1]

Summary of Key Points Core Viewpoint - The company, Jianyou Co., has announced a share buyback program, indicating a strategic move to enhance shareholder value amidst market conditions [1]. Group 1: Share Buyback Details - As of October 31, 2025, Jianyou Co. has repurchased approximately 1.38 million shares through the Shanghai Stock Exchange, representing 0.09% of the company's total share capital [1]. - The shares were bought at a minimum price of 9.56 CNY per share and a maximum price of 11.66 CNY per share [1]. - The total amount spent on the share buyback is approximately 15.01 million CNY [1].

国邦医药（605507）(605507.SH)发布公告，截至2025年10月31日，公司通过集中竞价交易方式累计回 购股份537.53万股，已回购股份占公司总股本的比例为0.96%，成交的最高价为19.88元/股，最低价为 18.61元/股，已支付的总金额为1.03亿元(不含交易费用)。 ...

Core Viewpoint - The company announced a share repurchase plan aimed at enhancing employee stock ownership and equity incentives, with a total repurchase amount expected to be between 100 million to 200 million yuan [1] Group 1 - The share repurchase will be conducted through centralized bidding and is set to last until March 10, 2026 [1] - As of October 31, 2025, the company has repurchased a total of 5.3753 million shares, which represents 0.96% of the total share capital [1] - The highest transaction price recorded during the repurchase was 19.88 yuan per share, while the lowest was 18.61 yuan per share, with a total expenditure of 103 million yuan [1]

南财智讯11月3日电，金达威发布公告称，公司及子公司厦门金达威维生素有限公司近日收到国家知识 产权局颁发的1件发明专利证书。专利名称为"一种6-氯-6-氧代己酸乙酯的连续制备装置及方法"。 ...